Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, New York.
Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, New York.
J Surg Res. 2024 Aug;300:477-484. doi: 10.1016/j.jss.2024.05.025. Epub 2024 Jun 14.
Donor blood transfusion may potentially affect transplant outcomes through an inflammatory response, recipient sensitization, or transmission of infection. The aim of this study was to evaluate the association of donor blood transfusion with outcomes of liver transplantation (LT).
From January 2004 to December 2022, donor blood transfusion information was available for 113,017 adult recipients of LT in the United Network for Organ Sharing database and was classified into 4 levels of transfusion: no-transfusion (N = 68,130), transfusion of 1-5 units (N = 33,629), 6-10 units (N = 8067), and >10 units (N = 5329). Recipient survival analysis was performed by Kaplan-Meier method and multivariable Cox-hazard model.
Among this cohort, 40.8% of donors (N = 46,261) received blood transfusion during the index hospitalization. Compared to no-blood transfusion donors, blood transfusion donors were younger (median age 37 versus 46 y P < 0.001) and were more brain death donors (94.5% versus 92.1%, P < 0.001). An increased risk of rejection at 6-mo (transfusion 10.3% versus no-transfusion 9.9%, P = 0.055) and 1 y (transfusion 12.5% versus no-transfusion 11.9%, P = 0.0036) post-LT was noted in this cohort. Multivariable Cox-hazard model showed blood transfusion was associated with increased 1-y mortality (transfusion 1.07; 95% CI 1.02-1.12, P = 0.007) and graft failure (transfusion 1.09; 95% CI 1.04-1.13, P < 0.001).
Donor blood transfusion was associated with an increased risk of rejection at 6 mo and 1 y among LT recipients and worse post-transplant graft and overall survival. Additional information regarding donor blood transfusion, along with other known factors, may be considered when deciding the optimization of overall immune suppression in LT recipients to decrease the risk of delayed rejection.
供体输血可能通过炎症反应、受者致敏或感染传播对移植结果产生影响。本研究的目的是评估供体输血与肝移植(LT)结果的关系。
2004 年 1 月至 2022 年 12 月,美国器官共享网络数据库中 113017 例成人 LT 受者的供体输血信息可用,并分为 4 个输血水平:无输血(N=68130)、输血 1-5 单位(N=33629)、输血 6-10 单位(N=8067)和>10 单位(N=5329)。通过 Kaplan-Meier 方法和多变量 Cox 风险模型进行受者生存分析。
在该队列中,40.8%的供体(N=46261)在指数住院期间接受了输血。与未输血供体相比,输血供体更年轻(中位年龄 37 岁 vs 46 岁,P<0.001),脑死亡供体比例更高(94.5% vs 92.1%,P<0.001)。该队列中,6 个月(输血 10.3%vs 未输血 9.9%,P=0.055)和 1 年(输血 12.5%vs 未输血 11.9%,P=0.0036)时排斥反应的风险增加。多变量 Cox 风险模型显示,输血与 1 年死亡率(输血 1.07;95%CI 1.02-1.12,P=0.007)和移植物失败(输血 1.09;95%CI 1.04-1.13,P<0.001)相关。
供体输血与 LT 受者 6 个月和 1 年时排斥反应的风险增加以及移植后移植物和总体生存率下降相关。在决定优化 LT 受者的整体免疫抑制以降低延迟排斥风险时,可考虑有关供体输血的其他信息以及其他已知因素。